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Effect of dietary protein restriction on prognosis in patients dence of end-stage renal disease (ESRD) or death in pa-
with diabetic nephropathy. tients with non-diabetic nephropathies and slows the pro-
Background. Recent data suggest that dietary protein re- gression of diabetic nephropathy [3]. However, the lat-striction improves survival and delays the progression to end-
ter conclusion was based on 108 type 1 diabetic patients instage renal disease (ESRD) in non-diabetic nephropathies. The
five studies (mean length of follow-up, 4.5 to 35 months)purpose of our study was to determine the effect of dietary
protein restriction on survival and progression to ESRD in [4–8] applying changes in urinary albumin excretion rate
diabetic nephropathy. or the decline in GFR or creatinine clearance as end-
Methods. A four-year prospective, controlled trial with con- points. Flaws in design, randomization procedure, pa-cealed randomization was performed comparing the effects of
tient selection, methods and end-points in addition toa low-protein diet (0.6 g/kg/day) with a usual-protein diet. The
study included 82 type 1 diabetic patients with progressive the confounding impact of antihypertensive treatment
diabetic nephropathy [pre-study mean decline in glomerular suggest that the above-mentioned conclusion in relation
filtration rate (GFR) 7.1 mL/min/year (95% CI, 5.8 to 8.5)]. to diabetes should be interpreted with caution [9–12].
The main outcome measures were decline in GFR and develop-
We report the results of a four year, prospective con-ment of ESRD or death.
trolled trial with concealed randomization, comparingResults. During the follow-up period the usual-protein diet
group consumed 1.02 g/kg/day (95% CI; 0.95 to 1.10) as com- the effect of a low-protein diet with a usual-protein diet
pared with 0.89 (0.83 to 0.95) in the low-protein diet group in 82 type 1 diabetic patients with progressive diabetic
(P  0.005). The mean declines in GFR were 3.9 mL/min/year nephropathy. The study tested the hypothesis that a re-(2.7 to 5.2) in the usual-protein diet group and 3.8 (2.8 to 4.8)
duction in dietary protein intake retards the progressionin the low-protein diet group. ESRD or death occurred in 27%
to ESRD and improves survival in type 1 diabetic pa-of patients on a usual-protein diet as compared with 10% on
a low-protein diet (log-rank test; P  0.042). The relative risk tients with diabetic nephropathy.
of ESRD or death was 0.23 (0.07 to 0.72) for patients assigned
to a low-protein diet, after an adjustment at baseline for the
presence of cardiovascular disease (P  0.01). Blood pressure METHODS
and glycemic control were comparable in the two diet groups
The study was a prospective, randomized, unmasked,during the follow-up period.
Conclusion. Moderate dietary protein restriction improves controlled trial carried out at the Steno Diabetes Center.
prognosis in type 1 diabetic patients with progressive diabetic With concealed randomization the patients were in blocks
nephropathy in addition to the beneficial effect of antihyper- of two according to the level of GFR (50, 50x75,
tensive treatment.
75x100, 100 mL/min/1.73 m2), assigned to receive
either a usual-protein diet or a low-protein diet. All
patients were recruited at the Steno Diabetes Center
Dietary protein restriction slows the progression of
and seen by the same physician (HPH) and dietitian
renal disease and improves survival in animals with var-
(ETL) at each visit. The local ethics committee approved
ies glomerulopathies [1, 2]. Recently, a meta-analysis
the study, and all patients gave written informed consent.
suggested that dietary protein restriction lowers the inci-
Patients and randomization
The following inclusion criteria were used: PatientsKey words: type 1 diabetes, survival, ESRD, GFR, progressive renal
disease, protein restriction, diabetic nephropathy. between 18 and 60 years of age with type 1 diabetes
mellitus for at least 10 years, with an onset before theReceived for publication September 4, 2001
age of 35 years, presence of diabetic retinopathy, albu-and in revised form January 31, 2002
Accepted for publication February 21, 2002 minuria 300 mg/24 h in at least two out of three sterile
urine samples, and no clinical or laboratory evidence of 2002 by the International Society of Nephrology
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other kidney or urinary tract disease [13], GFR above ization and during follow-up, GFR was measured on the
basis of the plasma clearance of an intravenous injection20 mL/min/1.73 m2 and a pre-study decline in GFR 2
mL/min/year (progressive diabetic nephropathy). Since of 51Cr-EDTA over a four-hour period starting at 8 am
[18]. The results were standardized for 1.73 m2 body sur-patients continued their usual antihypertensive treat-
ment, reduction in albuminuria even into the normal face area, using the same surface for each patient during
the study.range was observed in some of the patients at entry,
as previously demonstrated by us [14, 15]. Presence of Blood pressure was measured on the right arm with
a Hawksley Random Zero Sphygmomanometer. The in-pregnancy, a history of congestive heart failure or myo-
cardial infarction or coronary bypass surgery within the dividual blood pressure level was determined as the
mean of at least two measurements. The mean bloodlast three months resulted in exclusion. Eighty-two type 1
diabetic patients who fulfilled the inclusion criteria con- pressure was calculated {[(systolic blood pressure (2
diastolic blood pressure)]/3}.secutively entered the study between May 1995 and April
1996 (Fig. 1). Body mass index (BMI) was calculated as weight (kg)
per height (m)2. Retinopathy was assessed by fundus
Study diet photography and graded simplex or proliferative retin-
opathy. Present smokers were defined as persons smok-After randomization an iso-caloric low-protein diet of
0.6 g/kg/day was prescribed to patients in the low-protein ing more than one cigarette/cigar/pipe per day.
A 12-lead electrocardiogram was recorded and sub-diet group. The same dietitian (ETL) gave nutritional
advises, based on estimated protein intake, at least every sequently coded using the Minnesota Rating Scale [19]
independently by two trained observers, who were maskedthree months during the whole study period (see below).
All patients in the low-protein diet group received sup- to the clinical status of the patients. Coronary heart dis-
ease was diagnosed if the electrocardiogram showedplementation of calcium of 500 mg/day. The usual-pro-
tein diet consisted of the patients’ pre-study diet. In the signs of myocardial infarction or ischemia, or if patients
reported a history of myocardial infarction according tolow-protein diet group (N  4), urine albumin losses 2
g/day were replaced by increasing dietary protein on a the World Health Organization criteria [20] and vali-
dated by hospital records.gram-for-gram basis, only if the patient was compliant
with the prescribed low-protein diet.
Outcome measures
Procedures and measurements The main outcome measures were the rate of decline
in GFR and the cumulative incidence of ESRD requiringThe planned duration of follow-up was four years in
each patient. At randomization and scheduled visits ev- dialysis or transplantation, and death. Slopes were calcu-
lated on the basis of the baseline GFR and all follow-upery three-month all patients gave a complete history of
medication, underwent examination of weight, urinary values. Before the development of uremic symptoms,
patients (N  6) were referred to the department ofalbumin-, sodium- and urea excretion, serum albumin,
serum urea, hemoglobin, hemoglobin A1c (normal range; nephrology at the University Hospital of Herlev or Rigs-
hospitalet, when GFR deteriorated below 10 to 20 mL/4.1 to 6.4%), blood pressure, serum total-cholesterol and
high-density lipoprotein (HDL) cholesterol. GFR, serum min/1.73 m2, where accepted criteria for initiation of dial-
ysis and transplantation were applied on patients fromtriglycerides, calcium and phosphorous, anthropometric
measurements, nutritional status and smoking habits both diet groups. These patients continued their sched-
uled visits and treatment in the study until the end of thewere evaluated every six months. Apart from the urine
collections, all the measurements were carried out with four-year follow-up. Cause of death was obtained from the
death certificate. An independent observer without knowl-the patients in the supine position. Chemical and bio-
chemical analyses of serum and urine were performed edge of randomization reviewed all death certificates and
the primary cause of death was recorded. Conditionsby standard laboratory techniques.
Dietary protein intake was estimated on the basis of requiring withdrawal from the study included intercur-
rent illness (cancer, N 3; stroke, N 1) that precludedthree consecutive 24-hour urine samples completed
before each visit, using the urinary excretion of urea the patients continued participation in the study.
nitrogen (UUN) as follows [16]: estimated protein in-
Statistical analysistake (g/day)  6.25 · [UUN (g/day)  standard body
weight (kg) · 0.031 (g/kg/day)]. All consumed protein Data for blood pressure, hemoglobin A1c and albumin-
uria during the period before randomization were aver-is reported.
Before randomization, GFR was measured either by aged for each year for each patient and used to determine
a mean value for the entire period. Linear regressionthe plasma clearance of 51Cr-EDTA (N  58) or the
formula of Cockroft and Gault (usual-protein diet group; analysis was used to estimate the rate of decline in GFR
for each patient before and during the present studyN 11, low-protein diet group; N 13) [17]. At random-
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Table 1. Clinical characteristics of type 1 diabetic patients with diabetic nephropathy at the time of randomization
Usual-protein diet Low-protein diet
Variable N  41 N  41
Sex female/male 18/23 11/30
Age years 41 (9) 40 (8)
Duration of diabetes years 28 (8) 27 (7)
Duration of diabetic nephropathy years 10 (5) 9 (5)
Insulin u/kg/24 h 0.60 (0.16) 0.67 (0.18)
Dietary protein intake g/kg/24 h 1.04 (0.25) 0.97 (0.26)
Standard body weight kg 68 (9) 72 (8)
Body mass index kg/m2 25 (3) 25 (4)
Systolic blood pressure mm Hg 138 (18) 142 (17)
Diastolic blood pressure mm Hg 79 (10) 81 (9)
Retinopathy simplex/proliferative 12/29 9/32
GFR mL/min/1.73 m2 67 (32) 69 (30)
Albuminuriaa mg/24 h 737 (1.2) 681 (1.2)
Urinary sodium excretion rate mmol/24 h 166 (58) 151 (52)
Cardiovascular events N (%)
Coronary heart disease 8 (20) 8 (20)
Stroke 2 (5) 3 (7)
I/D polymorphism in the ACE gene (%) 20/53/27 21/54/25
No. of antihypertensive drugs 0/1/2/3/3 7/7/15/9/3 8/6/13/9/5
Smoking N (%) 19 (46) 18 (44)
Hemoglobin A1c (%) 9.7 (1.4) 9.8 (1.6)
Blood hemoglobin mmol/L 8.2 (1.1) 8.2 (1.3)
Serum total-cholesterol mmol/L 5.4 (1.0) 5.5 (1.4)
Serum HDL-cholesterol mmol/L 1.43 (0.45) 1.32 (0.49)
Serum triglicerids mmol/L 1.17 (0.62) 1.70 (2.03)
Serum creatinine lmol/L 139 (62) 133 (48)
Serum urea mmol/L 9.1 (4.6) 9.1 (4.2)
Serum albumin g/L 36 (4) 37 (3)
Serum calcium mmol/L 1.24 (0.05) 1.23 (0.05)
Serum phosphorous mmol/L 1.30 (0.18) 1.25 (0.23)
None of the variables differed significantly between diet groups. Abbreviations are: I/D, insertion/deletion; ACE, angiotensin-converting enzyme; GFR, glomerular
filtration rate. Data are mean (SD) unless specified.
a Geometric mean (antilog SE)
using all the determinations of GFR. A minimum of one 2.5 mL/min/year between the two groups (  0.05, 	 
year of follow-up with at least three measurements of 0.10). Data are presented as means (SD or 95% CI)
GFR was required for a patient to be included in the except when indicated. Owing to the skewed distribution
slope analysis. Variables from the first visit after random- values for albuminuria was logarithmically transformed
ization and during the whole study were used to deter- before statistical analysis and given as geometric mean
mine the mean value for each patient. Using an intention- (range or 95% CI). Paired and unpaired t tests were used
to-treat approach, we related the rates of decline in to compare the results within or between the two diet
glomerular filtration, and cumulative incidence of ESRD groups. All calculations were made using SPSS for Win-
or death to the prescribed diet group. Kaplan-Meier dows (SPSS Inc., Chicago, IL, USA). P values less than
estimates of time to ESRD or death curves were com- 0.05 (two-sided) were considered to indicate significance.
pared by log-rank test. In the analysis of predictors of
ESRD or death, the Cox regression model was used. A
RESULTSmultiple regression analysis was performed with rate of
Clinical characteristics of patients in the two dietdecline in GFR as the dependent variable and backward
groups are shown in Table 1. No patients were lost toselection including variables (dietary protein intake,
follow-up (Fig. 1).mean arterial blood pressure, hemoglobin A1c, albumin-
uria and total cholesterol) with P 0.10 in an univariate
Dietary protein intake and nutritional statusanalysis. Before the present study, we analyzed the rate
After randomization and within the first three monthsof decline in GFR in 106 type 1 diabetic patients with
of the study, there was an initial decline in the dietaryprogressive diabetic nephropathy. Applying the ob-
protein intake of 0.06 g/kg/day (P  0.24) in the usual-tained standard deviation (3.2) for the rate of decline in
protein diet group and 0.15 g/kg/day (P  0.01) in theGFR (6.8 mL/min/year), in a sample size calculation we
low-protein diet group (P 0.22 between groups; Fig. 2).found that 34 patients were necessary in each diet group
to detect a difference in the rate of decline in GFR of After three months and during follow-up, the patients
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Fig. 1. The study profile.
Fig. 2. Estimated dietary protein intake in type 1 diabetic patients with progressive nephropathy. Symbols are: () usual-protein diet; () low-
protein diet. Values for the estimated dietary protein intake are mean and the 95% CI is indicated by the whiskers. The numbers of patients with
an estimated dietary protein intake at each visit are shown below the panel.
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Fig. 3. Cumulative incidence of end-stage renal disease (ESRD) or death in type 1 diabetic patients with progressive diabetic nephropathy in the
usual-protein group (dashed lines) and the low-protein diet group (solid line). Log rank text, P  0.042. The numbers at the bottom denote the
number of patients in each group at risk for the event at baseline and after each six month period.
in the usual-protein diet group consumed a mean of 1.02 min/year during a median follow-up of 4.9 (range, 1.0 to
(0.95 to 1.10) g/kg/day, as compared with 0.89 (0.83 to 11.2) years. Within the first six months of follow-up there
0.95) g/kg/day in the low-protein diet group (P  0.005, was a comparable significant decline in GFR of 4.1 mL/
Fig. 2). From baseline during follow-up the mid-arm min (P  0.01) in the usual-protein diet group and 4.4
circumference, serum albumin and body weight were mL/min (P  0.01) in the low-protein diet group (P 
comparable in the two diet groups (data not shown). 0.87 between groups). From randomization the rate of
decline in GFR slowed significantly in both diet groups
Dialysis, transplantation and death
during the four years of follow-up (3.9 mL/min/year in
At the end of the study six patients had required dial- the usual-protein diet group vs. 3.8 in the low-protein diet
ysis or renal transplantation and nine patients had died. group), while urinary albumin excretion rate remained
Causes of death were heart failure (N  4) and myocar- unchanged (Table 2). The average improvement of the
dial infarction (N 5). Dialysis, transplantation or death rate of decline in GFR, comparing slopes before and
occurred in 27% of patients (dialysis, N 3; transplanta- after randomization, were comparable in the two diet
tion, N  1; death, N  7) on the usual-protein diet, as groups; 2.7 (1.1 to 4.3) mL/min/year in the usual-protein
compared with 10% in patients (dialysis, N  2; death, diet group and 3.7 (1.6 to 5.9) mL/min/year in the low-
N  2) on the low-protein diet (log-rank test, P 0.042;
protein diet group (P  0.44). Geometric mean of albu-Fig. 3). The curves reflecting the cumulative incidence
minuria was comparable between diet groups during theof ESRD or death continued the separation during the
follow-up (Table 2).whole study period. A Cox regression analysis revealed
a relative risk of ESRD or death of 0.23 (0.07 to 0.72; Glycemic control, blood pressure, serum lipids
P  0.01) for the patients assigned to the low-protein and urea
diet group, compared with those assigned to the usual-
Hemoglobin A1c and blood pressure values were com-protein diet group, after adjustment for the presence at
parable during follow-up in the two diet groups (Table 2).baseline of cardiovascular disease.
Blood pressure was equally significantly reduced during
Renal function the study compared to the pre-study period in both diet
groups, while hemoglobin A1c was significantly reducedBefore randomization the rate of decline in GFR in
the whole group of patients was 7.1 (CI, 5.8 to 8.5) mL/ in the low-protein diet group (Table 2). During follow-
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Table 2. Rate of decline in GFR, albuminuria, blood pressure and sociations between the rate of decline in GFR and mean
hemoglobin A1c before and during the study in type 1 diabetic values during follow-up of blood pressure (P  0.001),patients with diabetic nephropathy
albuminuria (P  0.001), hemoglobin A1c (P  0.03),
Usual-protein diet Low-protein diet serum cholesterol (P  0.04) and dietary protein intakeN  34 N  38
(P  0.07). A multiple linear regression analysis using
Follow-up years
these parameters as independent variables and the rateBefore the study 5.1 (1.0 to 10.1) 5.0 (1.0 to 11.2)
During the study 4.0 (1.5 to 4.2) 4.0 (2.1 to 4.3) of decline in GFR as the dependent variable, showed
Rate of decline in GFR that an increase in mean blood pressure (of 10 mm Hg),
mL/min/year
hemoglobin A1c (of 1%) and albuminuria (10-fold) wereBefore the study 6.6 (5.2 to 8.1) 7.6 (4.9 to 10.2)
During the study 3.9 (2.7 to 5.2)a 3.8 (2.8 to 4.8)a associated with a significant worsening in the rate of
Albuminuria mg/24 h decline in GFR of 1.2 (0.2 to 2.3), 0.71 (0.08 to 1.35) and
Before the study 721 (502 to 1036) 690 (547 to 871)
1.94 (0.40 to 3.48) mL/min/year, respectively.During the study 614 (389 to 969) 542 (382 to 769)
Blood pressure mm Hg
Before the study
Systolic 138 (133 to 144) 140 (136 to 144) DISCUSSION
Diastolic 85 (82 to 87) 85 (83 to 88)
The main finding from our prospective, randomizedMean 102 (100 to 105) 104 (101 to 106)
During the study controlled trial is that patients with type 1 diabetes suffer-
Systolic 140 (135 to 146) 142 (138 to 146) ing from progressive diabetic nephropathy experience a
Diastolic 79 (76 to 81)b 80 (78 to 83)b
beneficial effect of moderate restriction in dietary pro-Mean 99 (97 to 102)c 101 (99 to 103)c
Hemoglobin A1c % tein on the development of ESRD or death. The benefi-
Before the study 9.6 (9.2 to 9.9) 9.8 (9.4 to 10.1) cial effect of protein restriction appeared within the first
During the study 9.6 (9.3 to 10.0) 9.5 (9.1 to 9.9)c
year, and persisted with continued treatment, as also has
Data are mean (95% CI). Except follow-up (median and range) and albumin- been demonstrated in non-diabetic nephropathies [21],uria (geometric mean and 95% CI), no significant differences were found between
diet groups. A minimum of 1 year of follow-up during the study with at least 3 suggesting that type 1 diabetic patients with progressive
measurements of GFR was required for a patient to be included in this analysis diabetic nephropathy are highly sensitive to dietary pro-(N  72).
a P  0.005, bP  0.001, cP  0.05 compared to the period before the study tein restriction. Despite the differences in event rates,
the decline in GFR in the two treatment groups did not
differ significantly, while both diet groups demonstrated
a progressive time-dependent reduction in the rate ofup, serum total-cholesterol [5.8 (5.5 to 6.1) mmol/L and
decline in GFR as compared to the period before ran-5.5 (5.2 to 5.8), respectively], high density lipoprotein
domization. Blood pressure, albuminuria, and glycemic(HDL)-cholesterol [1.44 (1.31 to 1.58) mmol/L and 1.42
control were independent risk factors for the deteriora-(1.26 to 1.58), respectively], triglycerides [1.47 (1.29 to
tion in GFR [15]. Statistical analyses were by intention-1.65) mmol/L and 1.59 (1.25 to 1.92), respectively] and
to-treat, that is, patients were included in their assignedserum urea [11.8 (9.9 to 13.7) mmol/L and 10.9 (8.9 to
diet group, regardless of the achieved dietary protein12.8), respectively] were comparable in the usual-protein
intake. A lack of adherence to the prescribed low-proteindiet group and the low-protein diet group.
diet by some patients would result in an underestimation
Medication and smoking of the true beneficial effect of the diet. The achieved
level of long-term dietary protein restriction reflects realAt baseline and during follow-up, a comparable num-
life in an outpatient clinic set-up. Since diabetic patientsber of patients in both diet groups received antihyperten-
have other restrictions to the diet, this may reduce com-sive treatment, angiotensin-converting-enzyme inhibitors,
pliance to an additional low-protein diet. Although bet-diuretics,  and 	 blockers, calcium channel blockers,
ter compliance can be obtained by applying much morelow-dose acetylsalicylic acid and lipid lowering agents,
intensive dietary counseling [4, 5, 22], it is not easy torespectively (Table 3). At baseline and at follow-up num-
lower dietary protein intake to less than 0.8 g/kg/daybers of smokers were comparable in the two diet groups.
over extended periods of time [23], and patients withNumbers of smokers was reduced to 13 in the usual-
advanced non-diabetic renal disease are only able toprotein diet group, and to 14 in the low-protein diet
lower their protein intake by 0.1 to 0.2 g/kg/day despitegroup during follow-up.
intensive nutritional counseling [24]. Our study did not
Regression analyses for pooled data reveal the mechanisms of the beneficial effect of moder-
ate protein restriction, since neither the measured car-For all patients with cardiovascular disease at baseline
diovascular risk factors, nor the pharmacological treat-(regardless of randomization) the relative risk of ESRD
ment, or progression promoters in relation to kidneyor death were 14.2 (4.4 to 45.6; P  0.0001). Age and
disease showed any significant differences between thesex were excluded from the model. Univariate regression
analyses revealed significant or borderline significant as- two diet groups.
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Table 3. Medication at baseline and follow-up in 82 type 1 diabetic patients with diabetic nephropathy randomized to
either a usual-protein diet or a low-protein diet
At baseline N (%) At follow-up N (%)
Variable Usual-protein Low-protein Usual-protein Low-protein
Antihypertensive treatment 34 (83) 33 (80) 38 (93) 37 (90)
Angiotensin-converting enzyme inhibitors 29 (85) 29 (88) 33 (87) 33 (89)
Diuretics 26 (76) 28 (85) 33 (87) 33 (89)
- and 	-blockers 7 (21) 9 (27) 9 (24) 9 (24)
Calcium channel blockers 8 (24) 10 (30) 10 (26) 9 (24)
Low-dose acetylsalicylic acid 7 (17) 5 (12) 13 (32) 9 (22)
Lipid lowering agents (statins) 4 (10) 3 (7) 12 (29) 14 (34)
There were no significant differences in medication between diet groups at baseline or at follow-up.
The natural history of diabetic nephropathy is charac- diet and maximal effective doses of either enalapril or
losartan have proved to reduce renal fibrosis slightlyterized by an early progressive rise in systemic blood
pressure associated with a relentless decline in GFR of more effectively than treatment with a low protein diet
or angiotensin II blockade alone [36], suggesting thatapproximately 10 to 15 mL/min/year [25–27]. Blood pres-
sure elevation has proved to accelerate the progression dietary protein restriction also acts on pathways indepen-
dent of the renin-angiotensin system. Nevertheless, sinceof diabetic nephropathy [28]. Conversely, effective long-
term antihypertensive treatment reduces the rate of de- the majority of the renal protective effect of dietary
protein restriction seems to be mediated through thecline in GFR to approximately 5 mL/min/year [29], in
agreement with our present finding. The inverse correla- renin-angiotensin system, simultaneous treatment with
an angiotensin-converting enzyme inhibitor, widely usedtion between duration of antihypertensive treatment and
rate of decline in GFR demonstrated in the present study in the MDRD (Modification of Diet in Renal Disease)
study [22] and the present study, may have blunted theis in agreement with results previously obtained in dia-
betic and non-diabetic glomerulopathies, where a pro- additive beneficial effect of dietary protein restriction
on the decline in GFR in these two studies and albumin-gressive time-dependent reduction in the rate of decline
was obtained during long-term aggressive antihyperten- uria in the present study. When rate of decline in GFR
is slow, a time-to-event analysis has greater statisticalsive treatment [14, 30, 31]. The mechanisms of this time
dependent reduction in the rate of decline in GFR in power to detect a beneficial effect of an intervention
than an analysis based on the slope of GFR [37]. Thediabetic and non-diabetic nephropathies are unknown.
However, animal models of different kidney diseases REIN (Ramipril Efficacy in Nephropathy) and MDRD
studies support the validity of this analysis in non-dia-suggest a shift in the balance between synthesis and deg-
radation of extracellular mesangial matrix, preservation betic nephropathies [21, 38].
It should be emphasized, however, that a valid deter-of functioning (normal or only slightly damage) glomer-
uli, and even the possibility of new growth of glomerular mination of the rate of decline in GFR in patients with
chronic renal disease requires a reliable method for thecapillaries, as recently reviewed by Fogo [32]. It should
be recalled that the beneficial effect of improved gly- determination of GFR, repeated measurements of the
GFR, and a follow-up of at least two years [39]. Thesecemic control in The Diabetes Control and Complica-
tions Trial on the initiation and progression diabetic mi- requirements were fulfilled in our prospective study, ex-
cept for one patient with a follow-up period of only 18cro-angiopathy [33], or reversal of structural lesions in
diabetic glomerulopathy during normalization of gly- months. We have previously documented the validity of
the formula of Cockroft and Gault for the determinationcemic control with pancreas transplantation [34], are de-
layed for several years. Importantly, the improvement of the rate of decline in GFR [40].
We performed a prospective, randomized controlledin rate of decline in the present study will reduce the
power to detect a difference between the two diet groups. trial as compared to the previous trials examining the
effect of low-protein diet in type 1 diabetic patients, whichIn the present study, control of blood pressure rather
than dietary protein restriction was of major importance were carried out as non-randomized, or partly random-
ized, and/or self-controlled studies [4–8]. Type 1 diabeticfor the preservation of GFR during follow-up. Previous
experimental data have suggested that a low protein patients with normo- and microalbuminuria were en-
rolled in one study [8], while only type 1 diabetic patientsdiet, similar to treatment with an angiotensin-converting
enzyme inhibitor or an angiotensin II receptor blocker, with macroalbuminuria were enrolled in the remaining
studies. None of the previous studies required that pa-acts through a blockade of the renal renin-angiotensin
system [35]. However, the combination of a low protein tients also should have progressive diabetic nephropathy.
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tion in established renal injury in the rat. J Clin Invest 78:1199–All previous studies examined small numbers of patients;
1205, 1986
the largest study examined 35 subjects [5]. The main 3. Pedrini MT, Levey AS, Lau J, et al: The effect of dietary protein
restriction on the progression of diabetic and nondiabetic renaloutcome measures in our trial were time-to-event analy-
diseases: Meta-analysis. Ann Intern Med 124:627–632, 1996sis and rate of decline in GFR. Several of the previous
4. Walker JD, Bending JJ, Dodds RA, et al: Restriction of dietary
studies evaluated changes in urinary albumin excretion protein and progression of renal failure in diabetic nephropathy.
Lancet ii:1411–1415, 1989rate or short-term changes in creatinine clearance [6, 7],
5. Zeller KR, Whittaker E, Sullivan L, et al: Effect of restrictingthe latter confounded by dietary protein intake [41].
dietary protein on the progression of renal failure in patients with
Only Walker et al [4] and Zeller et al [5] performed insulin-dependent diabetes mellitus. N Engl J Med 324:78–84, 1991
6. Ciavarella A, Di Mizio G, Stefani S, et al: Reduced albuminuriavalid determinations of the rate of decline in GFR. The
after dietary protein restriction in insulin-dependent diabetic pa-reduction in rate of decline observed by Walker et al [4]
tients with clinical nephropathy. Diabetes Care 10:407–413, 1987
can partly be explained by the previously mentioned 7. Barsotti G, Ciardella F, Morelli E, et al: Nutritional treatment
of renal failure in type 1 diabetic nephropathy. Clin Nephrol 29:phenomenon of a progressive time-dependent reduction
280–287, 1988in the rate of decline in GFR as observed in the present
8. Dullaart RP, Beusekamp BJ, Meijer S, et al: Long-term effects
study and previous studies during antihypertensive treat- of protein-restricted diet on albuminuria and renal function in
IDDM patients without clinical nephropathy and hypertension.ment [14, 30]. Zeller et al found a rate of decline in GFR
Diabetes Care 16:483–492, 1993of 3.1 mL/min/year during the low-protein diet (0.72
9. Parving H-H: Low-protein diet and progression of renal disease
g/kg/day) [5], similar to what was found in both diet in diabetic nephropathy. (letter) Lancet 335:411, 1990
10. Parving H-H: Protein restriction and renal failure in diabetesgroups in our study and previously reported during long-
mellitus. N Engl J Med 324:1743–1744, 1991term aggressive antihypertensive treatment [13, 30],
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